No Data
No Data
JMP Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $470
TD Cowen Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $390
Q1 2025 Madrigal Pharmaceuticals Inc Earnings Call
Madrigal Pharmaceuticals: Strong Financial Performance and Strategic Positioning Justify Buy Rating
JMP Securities Reaffirms Their Buy Rating on Madrigal Pharmaceuticals (MDGL)
Earnings Call Summary | Madrigal Pharmaceuticals(MDGL.US) Q1 2025 Earnings Conference